PolyPid Ltd. (PYPD): Price and Financial Metrics
GET POWR RATINGS... FREE!
PYPD Stock Price Chart Interactive Chart >
PYPD Price/Volume Stats
|Current price||$9.28||52-week high||$19.45|
|Prev. close||$9.29||52-week low||$8.40|
|Day high||$9.38||Avg. volume||63,021|
|50-day MA||$9.31||Dividend yield||N/A|
|200-day MA||$10.58||Market Cap||158.19M|
PolyPid Ltd. (PYPD) Company Bio
PolyPid Ltd. is a clinical stage biopharmaceutical company focusing on the development, manufacture, and commercialization of administered therapies to improve surgical outcomes. The company was founded by Noam Emanuel in 2008 and is headquartered in Petach Tikva, Israel.
PYPD Latest News Stream
|Loading, please wait...|
PYPD Latest Social Stream
View Full PYPD Social Stream
Latest PYPD News From Around the Web
Below are the latest news stories about PolyPid Ltd that investors may wish to consider to help them evaluate PYPD as an investment opportunity.
PETAH TIKVA, Israel, June 02, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharma company aiming to improve surgical outcomes through locally administered, controlled, extended-release therapeutics, today announced that members of its executive management team will present at three upcoming healthcare investor conferences. Key presentation details include: The 2021 LD Micro Invitational XI Date: Thursday, June 10, 2021Time: 10:30 a.m. ET The JMP Securities Life Sciences
PolyPid (PYPD): Q1 GAAP EPS of -$0.47.As of March 31, 2021, the Company had cash and cash equivalents, short-term deposits and long-term deposits in the amount of $61.4 million, compared to $66.6 million at December 31, 2020. PolyPid (PYPD) continues to expect that this cash balance will be sufficient to fund operations...
Companies Reporting Before The Bell • PolyPid (NASDAQ: PYPD ) is estimated to report earnings for its first quarter. • Boyd Gaming (NYSE: BYD ) is projected to report quarterly earnings at $1.01 per share on revenue of $570.79 million. • Zealand Pharma (NASDAQ: ZEAL ) is likely to report quarterly loss at $1.01 per share on revenue of $9.89 million. • American Well (NYSE: AMWL ) is likely to report quarterly loss at $0.19 per share on revenue of $58.75 million. • Crescent Point Energy (NYSE: CPG ) is projected to report quarterly earnings at $0.03 per share on revenue of $492.10 million. • TORM (NASDAQ: TRMD ) is expected to report quarterly loss at $0.21 per share on revenue of $130.30 million. • Dream Finders Homes (NASDAQ: DFH ) is likely to report quarterly earnings at $0.19 per sha...
• Recruitment Progressing as Planned with Nearly 200 Patients Enrolled into Phase 3 SHIELD I Trial of D-PLEX100 in Abdominal Surgery • Recruitment Rate in SHIELD I trial Doubled in the Last Three Weeks • Manufacturing Facility Now Fully Scaled Up and Capable of Supporting at Least First 30 Months of Anticipated Commercial Demand for D-PLEX100 • Conference Call Scheduled for Today at 8:30 AM ET PETAH TIKVA, Israel, May 12, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharma company aiming to improve surgical outcomes through locally administered, controlled, extended-release therapeutics, today provided a corporate update and reported financial results for the three months ended March 31, 2021. Recent Corporate Highlights: Recruitment progressing as planned with ...
NEW YORK, NY / ACCESSWIRE / May 12, 2021 / Polypid Ltd (NASDAQ:PYPD) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 12, 2021 at 8:30 AM Eastern Time.To listen to the event live or access a replay of the call - visit https://www.
PYPD Price Returns